Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Neutrophil activation cause of inflammation in canine liver disease
Liver disease is a major health issue in dogs.
Research links high ammonia levels to immune response and inflammation

The Royal (Dick) School of Veterinary Medicine and The Roslin Institute have discovered that high levels of ammonia in dogs with liver disease causes an unregulated immune response by activating neutrophils. The resultant inflammation seen in these cases then further decreases the dog’s overall health.

Inflammatory molecules and high levels of ammonia are commonly discovered in canine liver disease cases and, while treating the liver disease generally results in a decrease in both ammonia and inflammation levels, it has not been known until now what caused the associated inflammation.

Inflammation is a natural and often useful immune response when infection is present, but it is thought that when this response is activated inappropriately, that significant detriment can occur within the body.

Craig R. Breheny, lead scientist involved in the research, states: “Liver disease is a huge issue both in human and veterinary medicine. This study shows how the relationship between ammonia and the inflammatory response strengthens the dog’s role as a model of the human condition”.

Treatment for liver disease is often supportive and the aetiology is largely unknown.

By closely observing the precise activity of these neutrophils, the researchers hope to develop improved treatment and to prevent this unregulated immune response. Breheny concludes: “By understanding how the disease works, new therapies can be investigated to the benefit of both veterinary and human patients”.

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.